common stock issuable upon conversion of the Series B convertible preferred stock and upon exercise of the warrants issued hereunder, collectively, as the securities.Our common stock is listed on the Nasdaq Capital Market under the symbol "AVGR." On February 7, 2018, the last reported sales price of our common stock was $4.23 per share.
additional financing when needed could force us to delay, reduce or eliminate our product development programs and commercialization efforts or cause us to become insolvent;•We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future;•Nasdaq may delist our securities from its exchange, which could harm our business and limit our stockholders' liquidity;•Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result
in decreases in the price of our common stock;•We have a history of net losses and we may not be able to achieve or sustain profitability;•Our limited commercialization experience and number of approved products makes it difficult to evaluate our current business, predict our
performance of our business and may result in decreases in the price of our common stock.Our quarterly and annual results of operations, including our revenues, profitability and cash flow, may vary significantly in the future and
clearances and approvals, particularly with respect to current and future generations of Pantheris;•market acceptance of our Lumivascular platform and products, including Pantheris;•the availability of reimbursement for our Lumivascular platform products;•our ability to attract new customers and increase the amount of business we generate from existing customers;•results of our clinical trials;•the timing and success of new product and feature introductions by us or our competitors or any other change in the competitive dynamics of our
industry, including consolidation among competitors, customers or strategic partners;•the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations;•changes in our pricing policies or those of our competitors;•general economic, political, industry and market conditions, including economic and political uncertainty caused by the recent U.S. presidential election;•the regulatory environment;•the hiring, training and retention of key employees, including our sales team;•the ability of our remaining sales and marketing personnel to maintain and increase our revenues after the April 2017 organizational
described below under "Risks Related to Ownership of our13Table of ContentsCommon Stock—Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.";•our ability to obtain additional financing; and•advances and trends in new technologies and industry standards.We have a history of net losses and we may not be able to achieve or sustain profitability.We have incurred significant losses in each period since our inception in 2007.
Our failure to achieve and sustain profitability would negatively impact the market price of our common stock.We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital
Given the recent decline in our stock price, any financing that we undertake in the next nine months could cause substantial dilution to our existing stockholders.To date, we have financed our operations primarily through sales of our products and net proceeds from the issuance of our preferred stock and debt financings, our "at-the-market"
versions of such products;•the costs, timing and outcomes of clinical trials and regulatory reviews associated with our future products;•the costs and expenses of maintaining or expanding our sales and marketing infrastructure and our manufacturing operations;•the costs and timing of developing variations of our Lumivascular platform products, especially Pantheris and, if necessary, obtaining FDA
interventional radiologists in the treatment of PAD;•the number and types of future products we develop and commercialize;•the costs of defending ourselves against existing and future litigation, including pending stockholder class action claims;•the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related
of our cash flow to fund working capital, capital expenditures and other general corporate purposes;•limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;•restrict us from exploiting business opportunities;•make it more difficult to satisfy our financial obligations, including payments on the Loan Agreement•place us at a competitive disadvantage compared to our competitors that have less debt obligations; and•limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, debt service requirements, execution of
covenants contained in the Loan Agreement could adversely affect our ability to:•finance our operations;•make needed capital expenditures;•make strategic acquisitions or investments or enter into alliances;•withstand a future downturn in our business or the economy in general;•refinance our outstanding indebtedness prior to maturity;•engage in business activities, including future opportunities, that may be in our interest; and•plan for or react to market conditions or otherwise execute our business strategies.We
and subject to a number of uncertainties, including our ability to obtain FDA clearance for new versions of Pantheris and other Lumivascular platform products we intend to commercialize in the United
not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.Our success depends in large part on a limited number of products, particularly Pantheris, all of which have
operations and use cash, which could reduce our cash faster than budgeted, cause us to need to obtain additional financing and have a material adverse effect on our operations and stock price.21Table of ContentsOur ability to compete is highly dependent on demonstrating the benefits of our Lumivascular platform to
sub-assemblies incorporated into our products would limit our ability to manufacture our products and could therefore harm our business, financial condition and results of operations.Our future growth depends on physician adoption of our Lumivascular platform products, which may require
The market price for our common stock may be influenced by many factors, including:•sales of stock by our existing stockholders, including our affiliates;•market acceptance of our Lumivascular platform and products, including Pantheris;•the results of our clinical trials;•changes in analysts' estimates, investors' perceptions, recommendations by securities analysts or our failure to achieve analysts' and our own
transaction expenses and the number of shares required to be sold to finance our operations.In addition, pursuant to our Securities Purchase Agreement with CRG, the Shelf Registration Statement also registered for resale 8,705 shares of common stock held by CRG, which may be